Trials / Completed
CompletedNCT01057251
Nebivolol in Patients With Systolic Stage 2 Hypertension
Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of 5 mg or 20 mg Nebivolol Once Daily on Blood Pressure in Patients With Systolic Stage 2 Hypertension
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 433 (actual)
- Sponsor
- Forest Laboratories · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
The primary object of this study is to evaluate the efficacy and safety of 6 weeks of nebivolol monotherapy compared with placebo in patients with systolic stage 2 hypertension.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Nebivolol | 5 mg, titrated to 20 mg, once daily oral administration |
| DRUG | Placebo | 5 mg or 20 mg once daily, oral administration |
Timeline
- Start date
- 2010-03-01
- Primary completion
- 2010-12-01
- Completion
- 2011-01-01
- First posted
- 2010-01-27
- Last updated
- 2012-01-11
- Results posted
- 2012-01-11
Locations
36 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01057251. Inclusion in this directory is not an endorsement.